AMM is the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society. The Alliance’s mission is to propel the future of mRNA medicines, improve patients’ lives, and advance scientific knowledge by empowering mRNA industry leaders, innovators, scientists, and other key stakeholders. Biomay’s membership in the AMM network enables the company to collaborate with leading organizations in the field, contribute to setting industry standards, and support the development of safe and effective mRNA-based therapies worldwide.
“Our membership in the Alliance for mRNA Medicines underscores our commitment to innovation and quality. By joining AMM, we gain valuable opportunities to exchange knowledge, strengthen our network, and actively contribute to the advancement of mRNA medicines for patients worldwide,” said Dr. Hans Huber, CEO at Biomay.
Biomay is also going to participate in the organisation’s annual meeting, AMM ASCENT (Advancements in mRNA Science, Commercialization, Education, and Novel Technologies) to take place in San Diego, CA (Coronado) September 16-18, 2025. Biomay’s VP Manufacturing, Dr. Hauke Hüttmann, is looking forward to meeting you there.
About Biomay
Biomay is a fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria. Founded in 1984, Biomay has specialized in the expression of recombinant proteins in E. coli from its inception. Today, the company provides cGMP services for the manufacturing of messenger RNA (mRNA), circular plasmid DNA, linear IVT-template DNA, and therapeutic recombinant proteins.
Biomay operates a dedicated mRNA Competence Center for cGMP manufacturing and QC testing of mRNA drug substance and drug product (clinical and commercial). Services include process and analytical development, cell banking, R&D material supply, cGMP manufacturing, lipid nanoparticle (LNP) formulation, and aseptic filling.
Biomay’s facilities are inspected by the US FDA.
Contact:
Dr. Angela Neubauer
SVP Client Business
request(at)biomay.com